---
title: "WBDE subsidiary Shishan Jianjia controlled-release tablets obtained ethical approval"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/246620235.md"
description: "WBDE's wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., recently received the review approval from the Ethics Committee of Xuanwu Hospital, Capital Medical University, for its Class 2 new drug Huperzine A controlled-release tablets, allowing it to conduct key registration clinical trials. This drug is used for the treatment of mild to moderate Alzheimer's-type dementia and employs a biphasic controlled-release technology aimed at improving patient compliance and reducing adverse reactions"
datetime: "2025-06-30T08:21:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/246620235.md)
  - [en](https://longbridge.com/en/news/246620235.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/246620235.md)
generator: "portal-rs"
---

# WBDE subsidiary Shishan Jianjia controlled-release tablets obtained ethical approval

According to the Zhitong Finance APP, WBDE (002082.SZ) announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., has recently obtained the ethical review approval from the Capital Medical University Xuanwu Hospital Ethics Committee for the key registration clinical trial of its Class 2.2 new drug Huperzine A controlled-release tablets for the treatment of mild to moderate Alzheimer's-type dementia, allowing the project to proceed.

Huperzine A controlled-release tablets are a Class 2.2 new drug independently developed by the company for the treatment of mild to moderate Alzheimer's-type dementia. It utilizes a biphasic controlled-release technology to smooth the drug release peak and valley curve, prolong the drug release time in the body, achieve rapid onset, reduce adverse reactions, and enhance the dosage with good safety. At the same time, the controlled-release technology allows for once-daily dosing, reducing frequency and improving patient compliance

### Related Stocks

- [002082.CN](https://longbridge.com/en/quote/002082.CN.md)

## Related News & Research

- [Church's Texas Chicken's China debut drew 2-hour lines — and $22 offers to wait in them](https://longbridge.com/en/news/297600833.md)
- [EUR 10,000,000 3.5% Secondary Market Notes (ISIN XS1524568679)(AIV22) - Delisting](https://longbridge.com/en/news/297678136.md)
- [Healey faces off against Minogue in quest for second term as Massachusetts governor](https://longbridge.com/en/news/297713455.md)
- [Live results: Massachusetts holds House primary contests](https://longbridge.com/en/news/297699105.md)
- [Germany successfully tests Israeli ballistic missile, officials say](https://longbridge.com/en/news/297747150.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**